Evidence map›Paper›PMID 40510358›Full record

ArticleFrontiers in immunology2025

Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy.

Wenjun Shu, Mingxu Yan, Lu Gan, Lu Li, Hongyue Tao, Zhiyu Peng, Jinghan Wang, Xiaofeng Li, Xintong Lin, Haifeng Chen and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Wenjun Shu *Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Mingxu Yan *Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Lu Gan *Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Lu LiDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Hongyue TaoDepartment of Radiology and Institute of Medical Functional and Molecular Imaging, Huashan Hospital, Fudan University, Shanghai, China.
Zhiyu PengEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Jinghan WangEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xiaofeng LiEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Xintong LinEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Haifeng ChenEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Jie GuoEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Kang XueEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Hongguang CuiDepartment of Ophthalmology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Heng LouEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Binbin XuEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Jinwei ChengEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Hongying YeDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Yiming LiDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Jiang QianEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Rui Zhang *Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Ruiqi Ma *Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Fangfang Zeng *Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tocilizumab (TCZ) has been demonstrated to be effective in treating thyroid-associated ophthalmopathy (TAO); however, its efficacy in hormone-resistant dysthyroid optic neuropathy (DON) remains unclear. This study aims to identify baseline and post-treatment indicators that can predict the necessity for surgical intervention following TCZ therapy. Methods: Thirty-one hormone-resistant DON patients treated with TCZ were categorized into surgery (n=15, 7 males, 8 females) and non-surgery (n=16, 8 males, 8 females) groups based on their post-TCZ surgical status. Retrospective comparisons between the two groups were performed using pre- and post-treatment ophthalmic assessments, biomarkers, and orbital magnetic resonance imaging (MRI) scans. The predictive value of identified variables was evaluated through receiver operating characteristic (ROC) curve analysis and logistic regression analysis. Results: The surgery group exhibited a significantly higher baseline thyroid-stimulating hormone receptor antibody (TRAb) ( Discussion: The percentage change in SIR(EOM/temporalis)

Indexed as

Antibodies, Monoclonal, HumanizedDecompression, SurgicalGraves OphthalmopathyOptic Nerve DiseasesAdultAgedBiomarkersFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkerstocilizumabmagnetic resonance imagingoptic neuropathythyroid-associated ophthalmopathythyroid-stimulating hormone receptor antibodytocilizumab

Identifiers

PMID40510358
PMCPMC12159062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.